



Professor Dr. med. Gerhard Behre was trained in hematology, oncology, and allogeneic hematopoietic stem cell transplantation at the Klinikum Großhadern, Ludwig-Maximilians-University of Munich, Germany. Scientifically we was trained at Harvard Institutes of Medicine, Beth Israel Deaconess Medical Center, Boston, USA. Currently we works as attending physician at the stem cell transplantation unit of the division of Hematology and Oncology at Leipzig University Hospital, Germany. His research interest is the role of transcription factor C/EBP α and microRNAs in myeloid differentiation and acute myeloid leukemia as well as the translational research in hematopoietic stem cell transplantation.

Selected publications:

1. Wurm AA, Zjablovskaja P, Kardosova M, Gerloff D, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Benoukraf T., Fricke S, Hilger N, Müller AM, Bill M, Schwind S, Tenen DG, Niederwieser D, Alberich-Jorda M, **Behre G**. Disruption of the C/EBP α - miR-182 balance impairs granulocytic differentiation, **Nat Commun.** **2017** Jun 29;8(1):46.
2. Pulikkan J, Tenen DG, **Behre G**. C/EBP α deregulation as a paradigm for leukemogenesis. **Leukemia**, **2017**, Jul 19. doi: 10.1038/leu.2017.229. [Epub ahead of print]
3. Wurm AA, Tenen DG, **Behre G**. The Janus-faced nature of miR-22 in hematopoiesis: Is it an oncogenic tumor suppressor or rather a tumor suppressive oncogene? **PLoS Genet.** **2017** Jan 12;13(1):e1006505
4. Gerloff D, Grundler R, Wurm AA, Bräuer-Hartmann D, Katzerke C, Hartmann JU, Madan V, Müller-Tidow C, Duyster J, Tenen DG, Niederwieser D, **Behre G**. NF- κ B/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. **Leukemia.** **2015** Mar;29(3):535-47.
5. Braeuer-Hartmann D, Hartmann J-U, Wurm AA, Gerloff D, Katzerke C, Verga Falzacappa M V, Pelicci PG, Mueller-Tidow C, Tenen DG, Niederwieser D and **Behre G**. PML/RAR α -regulated microRNA 181b targets tumor suppressor RASSF1A in acute promyelocytic leukemia. **Cancer Research** **2015** Aug 15;75(16):3411-24.
6. Katzerke C, Madan V, Gerloff D, Bräuer-Hartmann D, Hartmann JU, Wurm AA, Müller-Tidow C, Schnittger S, Tenen DG, Niederwieser D, **Behre G**. Transcription factor C/EBP α -induced microRNA-30c inactivates Notch1 during granulopoiesis and is downregulated in acute myeloid leukemia. **BLOOD.** **2013** Oct 3;122(14):2433-42.
7. Pulikkan JA, Peramangalam PS , Dengler V, Ho PA, Preudhomme C, Meshinchi S, Christopeit M, Nibourel O, Mueller-Tidow C, Bohlander SK, , Tenen DG, **Behre G**. C/EBP α regulated microRNA-34a targets E2F3 during granulopoiesis and is downregulated in AML with CEBPA mutations **BLOOD.** **2010** Dec 16;116(25):5638-49.
8. Pulikkan JA, Dengler V, Peramangalam PS, Peer Zada AA, Müller-Tidow C, Bohlander SK, Tenen DG, **Behre G**. Aberrant regulation of a molecular network comprising C/EBP α , microRNA-223 and E2F1 in acute myeloid leukaemia **BLOOD**, **2010** Mar 4;115(9):1768-78.
9. Pulikkan JA, Dengler V, Peer Zada AA, Kawasaki A, Geletu M, Pasalic Z, Bohlander SK, Ryo A, Tenen DG, **Behre G**. Elevated PIN1 expression by C/EBP α -p30 blocks C/EBP α induced granulocytic differentiation via c-Jun in AML. **Leukemia** **2010** May 24 (5):914-23.
10. Christopeit M, Schütte V, Theurich S, Weber T, Grothe W, **Behre G**. Rituximab reduces the incidence of acute graft-versus-host disease. **BLOOD** **2009** Mar 26;113(13):3130-1
11. Christopeit M, Schendel M, Föll J, Müller LP, Keysser G, **Behre G**: Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. **Leukemia** **2008** May;22(5):1062-4.
12. Geletu M, Balkhi MY, Peer Zada AA, Christopeit M, Pulikkan JA, Trivedi AK, Tenen DG, **Behre G**. Target proteins of C/EBP α -p30 in AML: C/EBP α -p30 enhances Sumoylation of C/EBP α -p42 via up regulation of Ubc9. **BLOOD** **2007** Nov 1;110(9):3301-9. Epub 2007 Aug 1
13. Pabst T, Mueller BU, Schoch C, Haferlach T, **Behre G**, Hiddemann W, Zhang DE, Tenen DG: AML1-ETO downregulates the granulocytic differentiation factor C/EBP α in t(8;21) myeloid leukemia. **Nature Medicine** 7: 444, **2001**
14. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, **Behre G**, Hiddemann W, Tenen DG: Dominant Negative Mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBP α), in acute myeloid leukemia. **Nature Genetics** 27: 263, **2001**